Greenyn Biotechnology Co., Ltd

Total Valuation

Greenyn Biotechnology Co., Ltd carries a market capitalization of 1.73B, placing it among publicly traded companies globally. Its enterprise value stands at 1.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Greenyn Biotechnology Co., Ltd currently has 27.03M shares outstanding.

Valuation Ratios

Greenyn Biotechnology Co., Ltd trades at a trailing price-to-earnings ratio of 13.64. The price-to-sales ratio is 2.17, and the price-to-book ratio stands at 3.10.

Enterprise Valuation

On an enterprise value basis, Greenyn Biotechnology Co., Ltd trades at an EV/EBITDA multiple of 9.25 and an EV/FCF ratio of 3.10. The EV/Sales ratio of 1.91 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.25 provides insight into valuation relative to core operating earnings.

Financial Position

Greenyn Biotechnology Co., Ltd maintains a current ratio of 6.84, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 93.56, indicating elevated leverage, while an interest coverage ratio of 15.77 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Greenyn Biotechnology Co., Ltd posts a return on equity of 23.36 and a return on invested capital of 10.39.

Taxes

Over the trailing twelve months, Greenyn Biotechnology Co., Ltd has paid 39.44M in income taxes, reflecting an effective tax rate of 21.33.

Stock Price Statistics

Greenyn Biotechnology Co., Ltd's stock has declined approximately -18.72611% over the past 52 weeks. The 50-day moving average sits at 68.02, while the 200-day moving average is 72.28.

Income Statement

Over the trailing twelve months, Greenyn Biotechnology Co., Ltd generated 915.32M in revenue and converted that into 145.52M in net income, yielding earnings per share of 4.64. EBITDA reached 188.81M, while operating income came in at 188.81M.

Balance Sheet

Greenyn Biotechnology Co., Ltd holds 1.15B in cash and equivalents against 915.56M in total debt, resulting in a net debt position of 69.52M. Total book value stands at 640.12M, with working capital of 1.27B providing operational flexibility.

Cash Flow

Greenyn Biotechnology Co., Ltd produced 158.90M in operating cash flow over the past twelve months. After subtracting -395.08M in capital expenditures, free cash flow totaled -236.18M - equivalent to -8.75 per share.

Margins

Greenyn Biotechnology Co., Ltd operates with a gross margin of 48.07, reflecting its pricing power and cost economics. The operating margin of 20.63 and net profit margin of 15.90 provide insight into operational efficiency.

Dividends & Yields

Scores

Greenyn Biotechnology Co., Ltd posts an Altman Z-Score of 2.75, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.